Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
Status:
NOT_YET_RECRUITING
Trial end date:
2029-08-01
Target enrollment:
Participant gender:
Summary
In this prospective, open-label, single-arm, single-institution trial, the investigators will accomplish the following two aims:
1. study the safety and tolerability of Ublituximab (Briumvi) twice annually in participants with early MS over a treatment observation period of \~12 months.
2. study the pre- and post-treatment change in plasma neurofilament light chain, tested at baseline pre-Ublituximab treatment, and q24 weeks for 96 weeks post Ublituximab treatment initiation.